Apoa5 (bd) Antibody [4H8H8E2 (c) ] | 32-110

Apoa5 (bd) Antibody [4H8H8E2 (c) ] | 32-110 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Ni-NTA purified truncated recombinant human APOA5 expressed in E. Coli strain BL21 (DE3) .

Research Area: Signal Transduction

Tested Application: E, WB

Application: Western Blot, ELISA.
Dilution:
Western Blot:1:500 - 1, 000
ELISA:Determining optimal working dilutions by titration test.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: 4H8H8E2 (c)

Isotype: IgG1

Conjugate: Unconjugated

Physical State: N/A

Buffer: Ascitic fluid containing 0.03% sodium azide.

Concentration: N/A

Storage Condition: Apoa5 (bd) monoclonal antibody can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: RAP3, UNQ411/PRO773, Apolipoprotein A5, Apo-AV, RAP3, APOAV

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglyc erides, whereas a knock-in model with human ApoA5 produced 50–70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor-_ agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Recently, it was demonstrated that ApoA5 is present in human serum detected by polyclonal antibodies against both the NH2 and COOH termini, although at much lower concentration than other apolipoproteins.